Keyphrases
Absolute Lymphocyte Count
13%
Allergy Disease
21%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Baricitinib
16%
Clinical Trial Data
8%
Clinically Significant
8%
Confidence Interval
19%
COVID-19
100%
COVID-19 Outcomes
8%
COVID-19 Pandemic
16%
COVID-19 Treatment
22%
Demographic Representation
8%
Disease Stage
8%
Disease Threat
8%
Doxycycline
8%
Emerging Infectious Diseases
9%
Guideline Dissemination
8%
Hazard Ratio
10%
Hospitalized Adults
25%
Immunomodulator
12%
Infectious Diseases
25%
Influenza
23%
Invasive Mechanical Ventilation
10%
Lessons Learned
8%
Meta-analysis
16%
Meta-analysis of Randomized Controlled Trials
8%
Monoclonal Antibody
9%
Multilineage
8%
National Institutes of Health
9%
Nursing Homes
11%
Pandemic Influenza Virus
8%
Phase II Trial
8%
Placebo
18%
Placebo-controlled Trial
8%
Post-cardiac Surgery
8%
Primary Graft Dysfunction
8%
Randomized Controlled Trial
14%
Randomized Placebo-controlled Trial
11%
Remdesivir
66%
Risk Profile
11%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
9%
Severe COVID-19
18%
Severe Disease
9%
Survival Benefit
8%
Systematic Meta-analysis
16%
Therapeutic Landscapes
8%
Treatment Algorithm
8%
Treatment Trials
37%
Underuse
8%
Universal Vaccine
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
5%
Baricitinib
33%
Biological Marker
8%
Clinical Trial
9%
Coronavirinae
30%
Corticosteroid
8%
COVID-19 Vaccine
8%
Dexamethasone
11%
Diseases
59%
Doxycycline
8%
Immunocompromised Patient
10%
Immunomodulating Agent
14%
Infection
33%
Live Attenuated Influenza Vaccine
8%
Multiple Myeloma
8%
Observational Study
9%
Pandemic
25%
Placebo
34%
Quinolone Derivative
8%
Randomized Controlled Trial
23%
Remdesivir
57%
Respiratory Virus
8%
SARS Coronavirus
25%
Secondary Infection
12%
Sudden Infant Death Syndrome
8%
Therapeutic Use
8%
Tolerability
8%
Medicine and Dentistry
Artificial Respiration
8%
Cell Transplantation
8%
Corticosteroid
8%
Corticosteroid Therapy
5%
COVID-19
58%
COVID-19 Vaccine
16%
Cyclophosphamide
8%
Cytopenia
8%
Diseases
11%
Emerging Infectious Disease
8%
Graft Failure
8%
Heart Rate Variability
6%
Heart Surgery
8%
Immunocompromised Patient
8%
Immunomodulating Agent
8%
Infection
22%
Infectious Disease
18%
Influenza A Virus
8%
Influenza Vaccine
16%
Lymphocytopenia
8%
Meta-Analysis
25%
Mycobacterium Chimaera
8%
Observational Study
9%
Odds Ratio
9%
Pandemic
8%
Post-Hoc Analysis
8%
Randomized Controlled Trial
10%
Remdesivir
8%
Sleep Time
5%
Splenomegaly
8%
Sudden Infant Death Syndrome
8%
Systematic Review
16%
Transplantation
8%
Treatment Effect
5%
Wearable Sensor
8%
